Learn how to overcome the optical interference associated with label-based screening methods for hit finding and characterization campaigns. https://okt.to/H0IUly
Discovery | Charles River
Biotechnology
Wilmington, MA 14,281 followers
Shouldn’t our next discovery be yours?
About us
Discovery from Charles River is industry-proven in the successful development of potential novel therapies, with over 100 preclinical drug candidates and over 420 patents delivered to our sponsors. Backed by more than 1,100 scientists, our comprehensive, multi-modality integrated portfolio employs the latest technology and platforms to provide chemistry, biology, pharmacology and toxicology services that support clients from the earliest stages of target discovery through IND. Our client-focused, collaborative approach creates true partnerships that anticipate challenges, overcome obstacles, and move us forward together on the journey of getting new drugs to market.
- Website
-
https://www.criver.com/products-services/discovery-services
External link for Discovery | Charles River
- Industry
- Biotechnology
- Company size
- 10,001+ employees
- Headquarters
- Wilmington, MA
Updates
-
How are industry conditions and advancing technologies changing the way we de-risk? Find out in this interview with industry expert Sarah Gould. Listen now: https://okt.to/EVYWDj
-
-
We understand the uncertainties and risks in small molecule drug discovery. Our transformative approach focuses on predictability, transparency, and your expedited success. With a fixed budget and key value-inflection points, our fully managed, risk-sharing model ensures no hidden costs or unreliable timelines. Our risk, your reward. Look deeper into the benefits of partnering with us. https://okt.to/qe1GOA #AI #drugdiscovery #pharmaceutical #Logica #smallmolecule
-
Our multidisciplinary #drugdiscovery team offers the expertise in RNA-based therapeutics to support your research goals. Talk to a discovery specialist today. https://bit.ly/3Unbq38
-
Meet Dr. Emilio Cordova, the Executive Director of Logica. With over 25 years of experience in contract research, Emilio has held leadership positions in sales, marketing, and business development. Before joining Logica, he successfully led SAMDI Tech, Inc. as CEO, culminating in its acquisition by Charles River in 2023. Get to know Emilio and the rest of our top-tier thought leaders. https://okt.to/Hand2t #AI #drugdiscovery #pharmaceutical #Logica
-
-
Learn how to integrate #biomarker discovery into the #drugdiscovery process with our on demand webinar. Watch now: https://okt.to/GIbCHX
-
-
The final ICH M12 DDI guidelines have just been published, promising a harmonized approach to assessing DDI risk. Join Noémi Szili DMPK product manager, Manu Kohli and Michael Shockley of Charles River, for our upcoming webinar to learn about the most important changes and updates, and how they may affect your program. Register here: https://okt.to/LC9Nao
-
-
How is the application of machine learning to Cryo-EM filling a capability gap in lipid nanoparticle research? Listen now to find out: https://okt.to/BuXixb
-
-
Learn how drug repurposing through cell painting could treat #raredisease in our latest #EurekaBlog: https://okt.to/RyWzNr
-
Wondering what Logica can do for your #drugdiscovery program? Logica is a combination of world-class wet lab data generation platforms with best-in-class machine learning chemical design technology and aims to deliver better leads for better drugs. And our risk-sharing and value-anchored structures provide a level of certainty unprecedented in #smallmolecule development. Partner with us and benefit from the combined expertise of Charles River and Valo Health ensuring you get a high-confidence candidate ready for clinical development. Want to learn more about the benefits of working with us? Check out our FAQs. https://okt.to/mCSUQ7
-